Menu
Colorectal Cancer is the third most common and second
most deadly cancer in Europe.
Despite the efforts of European countries to establish
successful screening programmes, the current participation
rates are only 14%.
Industry knowledge and continuous studies show the
beneficiary effects of early detection offered by public
screening programmes – yet most of us only get checked
once symptoms starts showing, often resulting in later stages
of the cancer.
We believe the way to increase the participation rate to the
EU goal of 65%, is by making these screening test as simple
as possible, providing an immediate result.
Colorectal Cancer is the third most common and second most deadly cancer in Europe.
Despite the efforts of European countries to establish successful screening programmes, the current participation rates are only 14%.
Industry knowledge and continuous studies show the beneficiary effects of early detection offered by public screening programmes – yet most of us only get checked once symptoms starts showing, often resulting in later stages
of the cancer.
We believe the way to increase the participation rate to the EU goal of 65%, is by making these screening test as simple as possible, providing an immediate result.
We revolutionise the way diagnostics based on faecal sampling are
made. Currently, we are developing a new medical point-of-care
device for the screening of colorectal cancer.
By changing the process of how colon cancer gets detected, thereby
directly increasing the participation rate within the screening program,
it is projected to have yearly savings in European Union of €3 billion.
Get in touch to learn more about our novel solution.
We revolutionise the way diagnostics based on faecal sampling are made.Currently, we are developing a new medical point-of-care device for the screening of colorectal cancer. By changing the process of how colon cancer gets detected, thereby directly increasing the participation rate within the screening program, it is projected to have yearly savings in European Union of €3 billion.
Get in touch to learn more about our novel solution.
By making our novel solution become the future Golden
Standard of public screening tests, we are able to replace the
inconvenient and time-consuming test that is offered today.
With our innovative hardware, we are able to improve the
overall experience of the citizen, while simultaneously
eliminating the steps that makes up for the most expensive
part of todays screening test.
We project to be available on the market from 2026, yet we
are already gaining impressive traction. Read more about our
milestones towards the final product, and how we are
revolutionising the public colorectal cancer screening test
down below.
By making our novel solution become the future Golden Standard of public screening tests, we are able to replace the inconvenient and time-consuming test that is offered today.
With our innovative hardware, we are able to improve the overall experience of the citizen, while simultaneously
eliminating the steps that makes up for the most expensive part of todays screening test.
We project to be available on the market from 2026, yet we are already gaining impressive traction. Read more about our milestones towards the final product, and how we are revolutionising the public colorectal cancer screening test down below.
Do you find our mission to improve the gut health
just as passionate as we do
Then come join our team.